inVentiv Health Names Dr. Michael McKelvey President, Clinical Division And Executive Vice President, inVentiv Health

Dr. McKelvey to Help Biopharmaceutical Clients Optimize the Development of Products for the Benefit of Patients Worldwide

inVentiv Health, a global provider of best-in-class clinical development and comprehensive commercialization services, recently announced the appointment of Michael McKelvey, Ph.D., as President, inVentiv Health Clinical Division and Executive Vice President, inVentiv Health. Dr. McKelvey is a seasoned veteran within the CRO industry and has a strong background in clinical development, technology and the development of innovative industry strategies.

Dr. McKelvey has extensive experience in building and managing successful global organizations in the pharmaceutical services, healthcare, information technologies, life sciences, technology and global core laboratory industries.

“Mike McKelvey has proven himself to be a hands-on leader who builds dynamic teams to tackle some of the most critical drug development issues facing the industry,” said Jeffrey P. McMullen, Chairman, inVentiv Health Clinical Division and Vice Chairman, inVentiv Health. “His vision is to incorporate innovation into the current drug development process by providing clients with an outsourcing model that embeds both clinical and commercial services.”

Throughout his career, Dr. McKelvey has developed a reputation for combining high-level strategic expertise with flawless execution. Before joining inVentiv Health, he served as Executive Vice President and Chief Operating Officer at Aptiv Solutions, a global clinical development services company focused on adaptive clinical trial design. Aptiv Solutions was acquired by ICON in 2014. Prior to Aptiv Solutions, he was President and CEO and a board member of eResearchTechnology, Inc. (ERT), a multi-product provider of clinical research services. Prior to ERT, Dr. McKelvey led PAREXEL’s Phase II-IV clinical operations for the Americas, as well as their global data management and global biostatistics groups.

“inVentiv Health’s portfolio of comprehensive clinical development and commercialization services offers a unique model for the streamlined delivery of drug development services to the patients who need them the most,” said Dr. McKelvey. “I am looking forward to engaging our global network of talented healthcare professionals to identify the best approaches for providing our clients with a competitive advantage.”

The inVentiv Health Clinical Leadership team, including Greg Skalicky, Chief Commercial Officer, Rick Shimota, Chief Financial Officer and Gregg Dearhammer, Chief Operating Officer, will continue in their roles, supporting Dr. McKelvey to help achieve the organization’s objectives.

“It’s a great time to have Mike join the organization,” said Michael Bell, Chairman and CEO, inVentiv Health. “His experience in global expansion, technology solutions and integration initiatives will serve us well. He’ll be a tremendous asset to our Executive Leadership team.”

The inVentiv Health Executive Leadership team is comprised of Michael Bell, Chairman and CEO, inVentiv Health, Michael Griffith, President, inVentiv Health Commercial Division and Executive Vice President, inVentiv Health and now Dr. McKelvey. Jeffrey McMullen will continue in his role as Chairman, inVentiv Health Clinical Division and Vice Chairman, inVentiv Health.

Dr. McKelvey holds a Ph.D. and M.A. in business economics from the Wharton School at the University of Pennsylvania and an A.B. degree in economics from Williams College.

About inVentiv Health
inVentiv Health is a global provider of best-in-class comprehensive clinical development and commercialization services, seamlessly linking the capabilities of a leading, global Clinical Research Organization (CRO) with a unique Contract Commercial Organization (CCO). inVentiv Health helps clients improve performance, reduce risk and speed much-needed therapies to market. With 13,000 employees providing services to clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies developing and delivering medicines in a complex operating, regulatory and reimbursement environment. Our clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team.

inVentiv Health brings business strategy to science and scientific expertise to business for the better treatment of patients worldwide. For more information, visit inVentivHealth.com.